Comparative Pharmacology
Head-to-head clinical analysis: DAPAGLIFLOZIN versus GLYXAMBI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DAPAGLIFLOZIN versus GLYXAMBI.
DAPAGLIFLOZIN vs GLYXAMBI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, reducing renal glucose reabsorption and lowering blood glucose.
GLYXAMBI is a combination of empagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Empagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin increases incretin hormones (GLP-1, GIP), enhancing insulin release and decreasing glucagon levels in a glucose-dependent manner.
10 mg orally once daily.
10 mg/5 mg orally once daily (empagliflozin/linagliptin). May increase to 25 mg/5 mg once daily if tolerated.
None Documented
None Documented
Clinical Note
moderateDapagliflozin + Gatifloxacin
"Dapagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateDapagliflozin + Rosoxacin
"Dapagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateDapagliflozin + Levofloxacin
"Dapagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateDapagliflozin + Trovafloxacin
"Dapagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12.9 hours (range 10-16 hours) for dapagliflozin, supporting once-daily dosing. At steady state, effective half-life is ~23 hours due to metabolite.
Empagliflozin: Terminal half-life ~12.4 hours allows once-daily dosing. Linagliptin: Terminal half-life >100 hours, but pharmacodynamic effect correlates with DPP-4 inhibition rather than plasma levels.
Primarily renal and fecal: ~75% of dose excreted in urine (as unchanged dapagliflozin and glucuronide conjugates), ~21% in feces. Biliary elimination is negligible.
Empagliflozin: Approximately 95.6% excreted in feces (41.2% as unchanged drug) and 54.4% in urine (19.8% as unchanged). Linagliptin: 84% excreted in feces via enterohepatic circulation (80% as parent drug) and 5% in urine.
Category C
Category C
SGLT2 Inhibitor
SGLT2 Inhibitor/DPP-4 Inhibitor Combination Antidiabetic